Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical
company focused on designing and developing targeted immunotherapies for the treatment of cancer
and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly
or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are:
TG4010, a therapeutic vaccine for non-small cell lung cancer and Pexa-Vec, an oncolytic virus for liver
cancer. The Company has several other programs in clinical and preclinical development. Transgene is
based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China.